Cargando…
Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma
SIMPLE SUMMARY: Since T-VEC is already approved for treatment of melanoma, its promising efficacy shown here also for NUT carcinoma (NC) cell lines may create a rapid transition to individual treatments as well as clinical trials in NC patients. The idea of combining T-VEC immunotherapy with BET inh...
Autores principales: | Ohnesorge, Paul V., Berchtold, Susanne, Beil, Julia, Haas, Simone A., Smirnow, Irina, Schenk, Andrea, French, Christopher A., Luong, Nhi M., Huang, Yeying, Fehrenbacher, Birgit, Schaller, Martin, Lauer, Ulrich M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179288/ https://www.ncbi.nlm.nih.gov/pubmed/35681742 http://dx.doi.org/10.3390/cancers14112761 |
Ejemplares similares
-
Starvation-Induced Differential Virotherapy Using an Oncolytic Measles Vaccine Virus
por: Scheubeck, Gabriel, et al.
Publicado: (2019) -
Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine
por: Binz, Eike, et al.
Publicado: (2017) -
Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms
por: Kloker, Linus D., et al.
Publicado: (2020) -
Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018) -
Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model
por: Koch, Jana, et al.
Publicado: (2023)